NCT03289637: D-Heart

Supplementation With Vitamin D to Patients With Heart Failure (D-Heart).

Status unknown NA Last updated 7 March 2018

What this trial tests

NA trial testing Vitamin D in Heart Failure With Reduced Ejection Fraction in 200 participants. Status unknown.

Timeline

1 February 2018

Primary endpoint
1 February 2019

1 February 2020

Quick facts

Lead sponsor	Linkoeping University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	200
Start date	1 February 2018
Primary completion	1 February 2019
Estimated completion	1 February 2020
Sites	1 location across Sweden

Drugs / interventions tested

• Vitamin D

Conditions studied

• Heart Failure With Reduced Ejection Fraction — all drugs for Heart Failure With Reduced Ejection Fraction →
• Vitamin D Deficiency — all drugs for Vitamin D Deficiency →

Sponsor

Linkoeping University

Who can join

Eligibility, any sex, with Heart Failure With Reduced Ejection Fraction or Vitamin D Deficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In 200 patients with documented systolic heart failure give supplementation with vitamin D in those with a 25-OH- vitamin D \< 50nmol/L - or placebo.

In those with a vitamin D level \<25nmol/L a substitution of 2400IU will be given, and in those with a vitamin D level 25-50nmol/L a substitution of 1600IU will be given.

Intervention time 12 months. Biomarkers of heart function, quality of life, and hospitalisation will be analysed.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Association of Serum 25-Hydroxyvitamin D Concentrations With All-Cause and Cause-Specific Mortality Among Adult Patients With Existing Cardiovascular Disease.
   Dai L, Liu M, Chen L. · · 2021 · cited 28× · PMID 34631770 · DOI 10.3389/fnut.2021.740855